Updating the operating model

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

1. 1

   Fragmented Bioprocess Data and Lack of Process Intelligence

   R&D scientists are bogged down by manual data collection and synthesis of disparate data streams from high-resolution microscopy, single-cell analysis, and long-term cell culture monitoring, leading to a 57% knowledge gap regarding sophisticated data utilization.

   Implementation of an Ontology-Driven Data Lakehouse to unify R&D and manufacturing data, mapping physical production parameters to a universal business class model for near real-time analytics and Quality by Design capabilities.

2. 2

   Scaling Cliff in Regenerative Tissue Production

   Current methodology for producing artificial pancreatic islets relies heavily on manual intervention and laboratory-scale prototypes, which are difficult to scale for massive volumes required in clinical trials and in-vivo testing.

   Transitioning to a Modular Facility of the Future using Module Type Package standardization, adopting a Plug and Produce approach with modular bioreactors and bioprinters that are easily scalable to accelerate time-to-market.

3. 3

   Regulatory Compliance Barrier for Clinical Transitions

   Reliance on manual R&D documentation and paper-based data capture becomes a strategic liability as Fluicell moves toward in-vivo development, introducing human error and creating a Paper Wall that hinders IP protection and regulatory submission quality.

   Deploying a GxP-compliant Digital Lab strategy prioritizing automated data capture and Electronic Batch Records, using IoT gateways to extract signals from instruments ensuring data integrity and zero-error audit standards.

4. 4

   R&D Cost Efficiency and Resource Management

   High burn rates and capital intensity require Fluicell to maximize every R&D dollar, but manual tasks like pipetting, agar prep, and colony counting consume excessive man-hours and introduce variability.

   Low-cost lab automation and technology retrofitting using control board to modernize existing R&D equipment without massive CAPEX, utilizing AI-based computer vision for automated cell counting to reduce manual labor by 80%.

5. 5

   Workforce Digital Skills Gap

   While scientific staff are well-regarded researchers, 57% lack the technical knowledge to manage sophisticated digital-native laboratory environments as the company scales toward clinical-grade manufacturing.

   Implementing structured digital onboarding programs and UX-driven interface redesigns that bridge the gap between scientific expertise and digital tool proficiency, enabling researchers to focus on high-value therapeutic discovery.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

• Self-assessment

  Find Your LIMS ↗

  Answer a few questions about your lab and get a shortlist of LIMS that fit it.

• Self-assessment

  Electronic Batch Record (eBR) Readiness ↗

  Check how far your batch records are from paperless, and what the next step is.

• Market comparison

  Digital Lab: Equipment & Integration Map ↗

  Which lab instruments connect to which systems, and where the gaps usually are.

• Market comparison

  European CDMOs Compared ↗

  The 2026 landscape: who does what, at what scale.

Related reading

• Still biotech or already techbio?

  The results of a Tech Imperatives for biotech 2022 report indicate changes in biotech production and management.

• From Paper to Performance: Operational Efficiency and Compliance in Labs

  Transform your QC lab with scalable digital solutions that embed compliance, boost efficiency, and deliver a future-ready competitive edge.

• Accelerating lab and manufacturing operations with MTP – a modular approach

  Among the various modular and plug-n-produce approaches, the Modular Type Package (MTP) approach has emerged as a game-changer.

• Developing a data and technology-driven flexible lab operations model

  Now, when it becomes clear to the biotech companies that only by sharing the data they can thrive, everyone is looking for a solution.

• Lab of Tomorrow: We’re at a Turning Point – Is Your Lab on the Right Track?

  Do you know what the biggest paradox is? Biotech and pharma fully understand that digitization is the future. Most of them know that effective market competition is simply not possible without artificial intelligence, automation, and data analysis. And yet, many labs are still stuck in the past, working in isolation, manually analyzing data, and losing the potential that technology offers.